A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Phase 3 Completed NCT05292586

Condition	Asthma
Phase	Phase 3
Sponsor	Chiesi Farmaceutici S.p.A.
Status	Completed
Enrollment	1,377 participants
Interventions	Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate
Start date	Aug 31, 2022
Completion date	Jun 24, 2024
Results posted	Sep 4, 2025

Summary

Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.

1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12

Baseline (pre-dose on Week 0) and Week 12. · liter

CHF 1535 pMDI	0.279 liter
CHF 718 pMDI	0.174 liter

p-value	<0.001
Adjusted mean difference	0.104 (95% CI 0.061–0.148)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma — ARS Pharmaceuticals, Inc.

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский